Home

Eli Lilly (LLY)

747.01
-8.10 (-1.07%)
NYSE · Last Trade: May 20th, 6:06 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close755.11
Open756.00
Bid745.33
Ask747.00
Day's Range743.00 - 763.50
52 Week Range677.09 - 972.53
Volume3,871,081
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield6.000 (0.80%)
1 Month Average Volume4,880,127

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Trump's $6 Trillion Investment Deals Face Reality Check: Only A Fraction May Reach The Real Economybenzinga.com
Despite $6 trillion in promised investments under Trump, Goldman Sachs estimates only $30B–$135B will meaningfully impact U.S. GDP.
Via Benzinga · May 20, 2025
Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Boughtbenzinga.com
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 20, 2025
Huge News for Eli Lilly Stock Investors!fool.com
Via The Motley Fool · May 18, 2025
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Againbenzinga.com
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Great News for Eli Lilly Stock Investors!fool.com
Via The Motley Fool · May 20, 2025
Ireland: America’s Gateway to Europe – The $2 Trillion Investment Story
Ireland has emerged as the undisputed champion in attracting U.S. foreign direct investment, hosting an extraordinary €897 billion (over $1 trillion) in American capital. This massive investment flow has transformed the small island nation into America's premier European platform, with U.S. affiliate assets reaching approximately $2 trillion in 2021.
Via AB Newswire · May 19, 2025
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giantsbenzinga.com
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auctioninvestors.com
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.
Via Investor's Business Daily · May 19, 2025
The Nasdaq Just Soared 30% From Its 2025 Low: 3 Vanguard ETFs to Buy Nowfool.com
Via The Motley Fool · May 18, 2025
Why Is Eli Lilly Stock Crashing and Is It a Buying Opportunity?fool.com
Via The Motley Fool · May 18, 2025
Got $1,000 to Invest? Buy This Top Vanguard ETF and Never Look Back.fool.com
Via The Motley Fool · May 17, 2025
MarketBeat Week in Review – 05/12 - 05/16
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts
Via MarketBeat · May 17, 2025
Eli Lilly Pulls Ahead Of Novo In Obesity Drug Gold Rush As New Players Crowd Intalkmarkets.com
Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up.
Via Talk Markets · May 16, 2025
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Todaybenzinga.com
Via Benzinga · May 16, 2025
Discover which S&P500 stocks are making waves on Friday.chartmill.com
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Via Chartmill · May 16, 2025
9 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 16, 2025
3 Stocks That Will Profit From Trump's Drug Price Cutbenzinga.com
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.
Via Benzinga · May 16, 2025
Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What's Driving Markets Friday?benzinga.com
Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade breakthroughs and recalibrate their economic expectations.
Via Benzinga · May 16, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 16, 2025
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Priceinvestors.com
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Via Investor's Business Daily · May 16, 2025
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Monthsfool.com
Via The Motley Fool · May 16, 2025
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pactbenzinga.com
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.
Via Benzinga · May 15, 2025
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing
Via MarketBeat · May 15, 2025
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocksfool.com
Via The Motley Fool · May 15, 2025